APTO earnings

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will p

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatmen

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2)   *Analysts interested in participating in the question-and-answer sess

Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile Continues with TUS/VEN Doublet TherapyConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today a

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast:    Date: Thursday, November 9, 2023 Time:  5:00 PM ETAudio Webcast Only: linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIb770b610b0744016870ec2150989ea78)  *Analysts interested in participating in the question-and-answer sessi

            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67% in Patients with Mutated FLT3 ─ ─ Data Guide to Accelerated Approval Path for TUS/VEN Doublet in Patients Who Failed Prior Venetoclax, Including FLT3 Mutated and Wildtype ─ ─ Hanmi Pharmaceutical Commits Investment in Aptose Up to 19.99% Ownership or $7 Million ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company de

SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Thursday, August 10, 2023Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BI29f5f8f4655b45cf8b92fd8f79f69f8f) *Analysts interested in participating in the question-and-answer session will pre-reg

─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Refractory AML Patients in APTIVATE Expansion Trial ─ ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial; Early Clinical Activity Already Noted ─ ─ Tuspetinib Superior Safety Profile Continues ─ ─ Luxeptinib G3 Formulation Continuous Dosing is Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose"

SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Monday, May 8, 2023Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:here(https://register.vevent.com/register/BI0c4e6d84e0b848f79be80dfa78e465bd) *Analysts interested in participating in the question-and-answer session will pre-register for

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended Dece

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:   Thursday, March 23, 2023  Time:  5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:here(https://register.vevent.com/register/BI9394078d0ea14714aca591ffe06992f1) *Analysts interested in participating in the question-and-

Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet Combination, Maintenance Therapy, and Patients Failed by Prior FLT3 InhibitorsTuspetinib Enrolling APTIVATE Expansion Trial for Monotherapy and Combination TherapyLuxeptinib Original Formulation Delivers New CR in DLBCL PatientLuxeptinib New G3 Formulation Continuous Dosing Ongoing in R/R AML PatientsAptose to Hold a Corporate Clinical Update and Data Review at 10:00 am EST SAN DIEGO and TORONTO and NEW ORLEANS, Dec. 11, 2022 (GLOBE NEWSW

─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Open for Tuspetinib Dose Expansion Trial with Enriched Populations ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib to Begin Soon ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, t

SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September 30, 2022, on Tuesday, November 1, 2022 after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, November 1, 2022  Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:here  (https://register.vevent.com/register/BIc687e1f1cee54e22b3d29e917044b145) *Please note the change in platform. Analysts interested in participating in

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple Genotypic Subpopulations ─ Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended June 30, 2022 and provided a corporate update. The net loss for the quarter e

SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:        Tuesday, August 2, 2022Time: 5:00 PM ETAudio Webcast Only: linkParticipant Registration Link*: here (https://register.vevent.com/register/BI8803d12ec6d04e93af962f01cbc8ae7d) *Please note the change in platform. Analysts interested in participating in the ques

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib "G3" formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. The net loss for the quarter ended March 31, 2022 was $11.5 million ($0.12 per share) compared with $16.2 million ($0.18 per share) for the quarter ended March 31, 2021. Total cas

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update.   Conference Call & Webcast:   Date: Monday, May 9, 2022  Time:  5:00 PM ETDial In - Toll-Free:   866-374-5140Dial In - International:  404-400-0571Conference ID:  38238231#Webcast:  link    The live conference call can also be accessed through a link on the Investor Relations section of Aptose's w

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway into fourth quarter of 2023 - - Conference call and webcast at 5:00 pm ET today - SAN DIEGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2021 and provided a corporate update. The net loss

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Tuesday, March 22, 2022Time:5:00 PM ETDial In - Toll-Free:1 844-882-7834Dial In - International:1 574-990-9707Conference ID:1644638Webcast:link The live conference call can also be accessed through a link on the Investor Relations section of Aptose's

- Conference call and webcast at 5:00 pm ET today - - HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline - - HM43239 phase 1/2 study in AML advances to 200 mg dose - - Luxeptinib phase 1a/b studies in AML/MDS and B cell malignancies advance to 900 mg dose - SAN DIEGO and TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months ended September 30, 2021 and provided a corporate update. The net loss for the quarter

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04, 2021 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), announced today that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly potent, clinical-stage myeloid kinome inhibitor (MKI), designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others. HM43239 has demonstrated significant genotype-agnostic

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market. Conference Call & Webcast:  Date:Thursday, November 11, 2021Time:5:00 PM ETDial In - Toll-Free:1 844-882-7834Dial In - International:1 574-990-9707Conference ID:5675957Webcast:link The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at https://

- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating patients at sixth dose cohort of 210 mg/m2 - SAN DIEGO and TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months ended June 30, 2021 and provided a corporate update. The net loss for the quarter ended June 30, 2021 was $13.5 million ($0.15 per share) compared

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market. Conference Call & Webcast: Date:                         Time:              Dial In - Toll-Free:  Dial In - International:             Conference ID:            Webcast:                     Tuesday, August 3, 2021  5:00 PM ET1 844-882-78341 574-990-97077272387https://edge.media-server.com/mmc/p/7gwifp